These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28769006)

  • 21. A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
    Ding N; Cui XX; Gao Z; Huang H; Wei X; Du Z; Lin Y; Shih WJ; Rabson AB; Conney AH; Hu C; Zheng X
    Int J Oncol; 2014 Jun; 44(6):2139-45. PubMed ID: 24647860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer.
    Andrzejewski T; Deeb D; Gao X; Danyluk A; Arbab AS; Dulchavsky SA; Gautam SC
    Oncol Res; 2008; 17(6):257-67. PubMed ID: 19192720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration.
    Hao Z; Liu Y; Liao H; Zheng D; Xiao C; Li G
    Exp Clin Endocrinol Diabetes; 2016 Apr; 124(4):246-50. PubMed ID: 27123784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells.
    Deeb D; Gao X; Dulchavsky SA; Gautam SC
    J Exp Ther Oncol; 2008; 7(1):31-9. PubMed ID: 18472640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
    Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
    Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atorvastatin Enhances Effects of Radiotherapy on Prostate Cancer Cells and Xenograft Tumor Mice Through Triggering Interaction Between Bcl-2 and MSH2.
    He Z; Yuan J; Shen F; Zeng F; Qi P; Wang Z; Zhai Z
    Med Sci Monit; 2020 Sep; 26():e923560. PubMed ID: 32870824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
    Yu P; Ye L; Wang H; Du G; Zhang J; Zhang J; Tian J
    Tumour Biol; 2015 Mar; 36(3):2143-53. PubMed ID: 25398692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer.
    Banerjee S; Zhang Y; Wang Z; Che M; Chiao PJ; Abbruzzese JL; Sarkar FH
    Int J Cancer; 2007 Feb; 120(4):906-17. PubMed ID: 17131310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
    Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
    Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth
    Tran LNK; Kichenadasse G; Morel KL; Lavranos TC; Klebe S; Lower KM; Ormsby RJ; Elliot DJ; Sykes PJ
    In Vivo; 2019; 33(1):99-108. PubMed ID: 30587609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133+CD44+ prostate cancer stem cells.
    Rentala S; Chintala R; Guda M; Chintala M; Komarraju AL; Mangamoori LN
    Biochem Biophys Res Commun; 2013 Nov; 441(3):586-92. PubMed ID: 24177008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.
    Ueno S; Kimura T; Yamaga T; Kawada A; Ochiai T; Endou H; Sakurai H
    J Pharmacol Sci; 2016 Jun; 131(2):110-7. PubMed ID: 27262901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.
    Gales L; Forsea L; Mitrea D; Stefanica I; Stanculescu I; Mitrica R; Georgescu M; Trifanescu O; Anghel R; Serbanescu L
    Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway.
    Deeb D; Jiang H; Gao X; Al-Holou S; Danyluk AL; Dulchavsky SA; Gautam SC
    J Pharmacol Exp Ther; 2007 May; 321(2):616-25. PubMed ID: 17289836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
    Chen J; Lan T; Hou J; Zhang J; An Y; Tie L; Pan Y; Liu J; Li X
    Int J Biochem Cell Biol; 2012 May; 44(5):759-69. PubMed ID: 22305890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells.
    Ghalali A; Wiklund F; Zheng H; Stenius U; Högberg J
    Carcinogenesis; 2014 Jul; 35(7):1547-55. PubMed ID: 24451147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model.
    Peng M; Su Q; Zeng Q; Li L; Liu Z; Xue L; Cheng Y; Huang Y; Tao T; Lv H; Li X; Tao X; Guo P; Chen AF; Yang X
    Oncotarget; 2016 Feb; 7(8):9102-17. PubMed ID: 26802022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
    Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.
    Roberts MJ; Yaxley JW; Coughlin GD; Gianduzzo TR; Esler RC; Dunglison NT; Chambers SK; Medcraft RJ; Chow CW; Schirra HJ; Richards RS; Kienzle N; Lu M; Brereton I; Samaratunga H; Perry-Keene J; Payton D; Oyama C; Doi SA; Lavin MF; Gardiner RA
    Contemp Clin Trials; 2016 Sep; 50():16-20. PubMed ID: 27370230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.